Seattle Genetics Company Profile (NASDAQ:SGEN)

About Seattle Genetics

Seattle Genetics logo

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company's product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC), comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE). The Company's pipeline includes other clinical-stage ADC programs, which are SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. SGN-CD33A is an ADC composed of an anti-CD33 monoclonal antibody indicated for the treatment of acute myeloid leukemia (AML). SGN-CD19A is an ADC composed of an anti-CD19 monoclonal antibody indicated for the treatment of hematologic malignancies. SGN-LIV1A is an ADC composed of an anti-LIV-1 monoclonal antibody indicated for the treatment of LIV-1-positive metastatic breast cancer.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: Biotechnology
Exchange: NASDAQ
Symbol: SGEN
CUSIP: 81257810

Key Metrics:

Previous Close: $55.83
50 Day Moving Average: $48.63
200 Day Moving Average: $41.19
52-Week Range: $140,516,000.00 - $26.02
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -66.46
P/E Growth: -3.23
Market Cap: $7.85B
Outstanding Shares: 140,516,000
Beta: 1.86

Profitability:

Net Margins: -27.21%
Return on Equity: -15.29%
Return on Assets: -11.79%

Debt:

Current Ratio: 5.88%
Quick Ratio: 5.32%

Additional Links:

Companies Related to Seattle Genetics:

Consensus Ratings for Seattle Genetics (NASDAQ:SGEN) (?)

Ratings Breakdown:	1 Sell Rating, 6 Hold Ratings, 7 Buy Ratings
Consensus Rating:	Hold (Score: 2.43)
Consensus Price Target:	$51.55 (7.67% downside)

Analysts' Ratings History for Seattle Genetics (NASDAQ:SGEN)

Show:

Date	Firm	Action	Rating	Price Target
9/16/2016	Leerink Swann	Reiterated Rating	Buy	$62.00
9/16/2016	Goldman Sachs Group Inc.	Downgrade	Neutral -> Sell
9/7/2016	Morgan Stanley	Initiated Coverage	Overweight	$60.00
7/27/2016	RBC Capital Markets	Reiterated Rating	Outperform
7/27/2016	Barclays PLC	Boost Price Target	Overweight	$48.00 -> $53.00
7/27/2016	SunTrust Banks Inc.	Boost Price Target	Neutral	$34.00 -> $38.00
7/27/2016	Cantor Fitzgerald	Downgrade	Buy -> Hold	$43.00
7/12/2016	Credit Suisse Group AG	Reiterated Rating	Buy
6/29/2016	Needham & Company LLC	Reiterated Rating	Buy	$60.00 -> $72.00
6/13/2016	HC Wainwright	Reiterated Rating	Buy	$65.00
5/19/2016	Cowen and Company	Reiterated Rating	Hold
2/11/2016	Oppenheimer Holdings Inc.	Reiterated Rating	Market Perform
2/10/2016	Piper Jaffray Cos.	Lower Price Target	Neutral	$44.00 -> $33.00
2/10/2016	JPMorgan Chase & Co.	Lower Price Target	Neutral	$45.00 -> $43.00
9/14/2015	Royal Bank Of Canada	Lower Price Target	Outperform	$56.00 -> $54.00
8/25/2015	William Blair	Reiterated Rating	Buy
2/11/2015	Bank of America Corp.	Reiterated Rating	Sell
2/9/2015	Jefferies Group	Set Price Target	Buy	$53.00

(Data available from 9/26/2014 forward)

Earnings History for Seattle Genetics (NASDAQ:SGEN)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
10/27/2016
7/26/2016	Q216	($0.32)	($0.23)	$94.56 million	$95.40 million	View	Listen
4/28/2016	Q116	($0.09)	($0.15)	$116.49 million	$111.15 million	View	Listen
2/9/2016	Q415	($0.20)	($0.18)	$88.00 million	$93.50 million	View	N/A
10/29/2015	Q315	($0.20)	($0.21)	$82.35 million	$84.10 million	View	Listen
7/30/2015	Q215	($0.26)	($0.38)	$78.21 million	$77.10 million	View	Listen
4/30/2015	Q1	($0.19)	($0.17)	$74.57 million	$82.20 million	View	Listen
2/10/2015	Q414	($0.25)	($0.22)	$68.34 million	$74.30 million	View	Listen
10/30/2014	Q314	($0.24)	($0.13)	$66.90 million	$75.80 million	View	Listen
7/31/2014	Q214	($0.23)	($0.14)	$65.04 million	$68.30 million	View	Listen
5/1/2014	Q114	($0.21)	($0.13)	$64.62 million	$68.30 million	View	Listen
2/11/2014	Q413	($0.24)	($0.13)	$59.50 million	$67.40 million	View	Listen
11/5/2013	Q313	($0.22)	($0.19)	$57.79 million	$71.00 million	View	Listen
7/31/2013	Q2 2013	($0.20)	($0.06)	$58.12 million	$773.60 million	View	Listen
5/7/2013	Q1 2013	($0.19)	($0.14)	$53.72 million	$57.32 million	View	Listen
2/12/2013	Q4 2012	($0.10)	($0.09)	$57.21 million	$63.90 million	View	Listen
11/7/2012	Q312	($0.14)	($0.12)	$52.79 million	$49.83 million	View	N/A
8/8/2012		($0.15)	($0.15)			View	N/A
5/8/2012		($0.11)	($0.11)			View	N/A
2/13/2012		($0.31)	($0.24)			View	N/A
11/3/2011		($0.46)	($0.35)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Seattle Genetics (NASDAQ:SGEN)

Current Year EPS Consensus Estimate: $-0.99 EPS
Next Year EPS Consensus Estimate: $-0.84 EPS

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	1	($0.15)	($0.15)	($0.15)
Q2 2016	1	($0.29)	($0.29)	($0.29)
Q3 2016	1	($0.35)	($0.35)	($0.35)
Q4 2016	1	($0.36)	($0.36)	($0.36)

(Data provided by Zacks Investment Research)

Dividend History for Seattle Genetics (NASDAQ:SGEN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Seattle Genetics (NASDAQ:SGEN)

Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 97.93%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
9/22/2016	Jonathan G Drachman	CMO	Sell	2,249	$56.75	$127,630.75
9/14/2016	Eric Dobmeier	COO	Sell	22,918	$54.04	$1,238,488.72
9/13/2016	Felix Baker	Director	Buy	447,311	$50.71	$22,683,140.81
9/8/2016	Clay B. Siegall	Insider	Sell	31,269	$50.08	$1,565,951.52
9/8/2016	Felix Baker	Director	Buy	414,016	$48.43	$20,050,794.88
8/23/2016	Eric Dobmeier	COO	Sell	12,589	$48.00	$604,272.00
8/22/2016	Clay B. Siegall	Insider	Sell	23,381	$46.59	$1,089,320.79
8/22/2016	Eric Dobmeier	COO	Sell	5,411	$46.59	$252,098.49
8/22/2016	Vaughn B. Himes	EVP	Sell	3,991	$46.59	$185,940.69
8/8/2016	Clay B. Siegall	Insider	Sell	11,660	$47.19	$550,235.40
7/27/2016	Clay B. Siegall	Insider	Sell	4,042	$45.20	$182,698.40
7/6/2016	Clay B. Siegall	CEO	Sell	7,618	$40.56	$308,986.08
6/6/2016	Clay B Siegall	CEO	Sell	22,083	$43.59	$962,597.97
6/2/2016	Darren S Cline	EVP	Sell	3,366	$42.07	$141,607.62
5/27/2016	Clay B Siegall	CEO	Sell	48,660	$40.41	$1,966,350.60
5/24/2016	Clay B Siegall	CEO	Sell	8,400	$40.09	$336,756.00
5/23/2016	Clay B Siegall	CEO	Sell	6,700	$40.12	$268,804.00
5/17/2016	Clay B Siegall	CEO	Sell	7,618	$35.16	$267,848.88
4/25/2016	Clay B Siegall	CEO	Sell	800	$40.00	$32,000.00
4/5/2016	Clay B Siegall	CEO	Sell	7,618	$36.12	$275,162.16
3/22/2016	Clay B Siegall	CEO	Sell	15,236	$35.52	$541,182.72
3/21/2016	Clay B Siegall	CEO	Sell	4,282	$35.01	$149,912.82
3/17/2016	Felix Baker	Director	Buy	124,065	$31.85	$3,951,470.25
3/16/2016	Felix Baker	Director	Buy	1,349,237	$32.10	$43,310,507.70
3/15/2016	Felix Baker	Director	Buy	661,093	$32.08	$21,207,863.44
3/14/2016	Felix Baker	Director	Buy	118,941	$33.77	$4,016,637.57
3/11/2016	Felix Baker	Director	Buy	694,666	$32.46	$22,548,858.36
3/8/2016	Felix Baker	Director	Buy	502,523	$22.66	$11,387,171.18
3/2/2016	Felix Baker	Director	Buy	675,922	$31.77	$21,474,041.94
3/1/2016	Felix Baker	Director	Buy	24,200	$31.24	$756,008.00
2/29/2016	Felix Baker	Director	Buy	251,722	$30.39	$7,649,831.58
2/26/2016	Felix Baker	Director	Buy	314,508	$29.55	$9,293,711.40
2/22/2016	Felix Baker	Director	Buy	1,001,471	$29.63	$29,673,585.73
2/17/2016	Felix Baker	Director	Buy	1,269,147	$30.43	$38,620,143.21
2/12/2016	John A. Orwin	Director	Buy	2,000	$28.33	$56,660.00
12/15/2015	Vaughn B. Himes	EVP	Sell	40,500	$39.94	$1,617,570.00
12/3/2015	Clay B. Siegall	CEO	Sell	3,720	$39.99	$148,762.80
11/20/2015	Felix Baker	Director	Buy	329,358	$43.94	$14,471,990.52
11/17/2015	Clay B Siegall	CEO	Sell	87,473	$45.40	$3,971,274.20
11/11/2015	Darren S Cline	SVP	Sell	5,769	$45.68	$263,527.92
11/10/2015	Felix Baker	Director	Buy	934,624	$42.95	$40,142,100.80
11/9/2015	Felix Baker	Director	Buy	507,300	$43.76	$22,199,448.00
11/6/2015	Eric Dobmeier	COO	Sell	17,452	$42.50	$741,710.00
11/6/2015	Felix Baker	Director	Buy	417,924	$41.94	$17,527,732.56
11/5/2015	David W Gryska	Director	Sell	10,000	$43.57	$435,700.00
11/4/2015	Clay B. Siegall	CEO	Sell	3,718	$43.14	$160,394.52
10/5/2015	Clay B. Siegall	CEO	Sell	3,718	$41.30	$153,553.40
9/3/2015	Clay B. Siegall	CEO	Sell	3,718	$40.12	$149,166.16
8/20/2015	Clay B. Siegall	CEO	Sell	31,754	$42.02	$1,334,303.08
8/20/2015	Darren S. Cline	SVP	Sell	2,231	$42.02	$93,746.62
8/20/2015	Eric Dobmeier	COO	Sell	8,548	$42.02	$359,186.96
8/20/2015	Jonathan G. Drachman	CMO	Sell	4,462	$42.02	$187,493.24
8/20/2015	Todd E. Simpson	CFO	Sell	5,825	$42.02	$244,766.50
8/20/2015	Vaughn B. Himes	EVP	Sell	5,997	$42.02	$251,993.94
7/6/2015	Clay B Siegall	CEO	Sell	3,718	$46.94	$174,522.92
6/3/2015	Clay B Siegall	CEO	Sell	3,718	$45.72	$169,986.96
5/21/2015	Felix Baker	Director	Buy	950,886	$42.49	$40,403,146.14
5/8/2015	Eric Dobmeier	COO	Sell	17,074	$40.38	$689,448.12
5/7/2015	Felix Baker	Director	Buy	1,032,664	$35.56	$36,721,531.84
3/10/2015	Felix Baker	Director	Buy	285,036	$34.66	$9,879,347.76
3/9/2015	Felix Baker	Director	Buy	275,717	$34.66	$9,556,351.22
3/4/2015	Felix Baker	Director	Buy	448,841	$34.84	$15,637,620.44
2/25/2015	Felix Baker	Director	Buy	281,115	$33.92	$9,535,420.80
1/6/2015	Clay B Siegall	CEO	Sell	16,804	$31.80	$534,367.20
12/16/2014	Felix Baker	Director	Buy	2,883,378	$31.86	$91,864,423.08
12/10/2014	Felix Baker	Director	Buy	1,247,896	$33.82	$42,203,842.72
12/9/2014	Felix Baker	Director	Buy	128,430	$34.16	$4,387,168.80
12/8/2014	Felix Baker	Director	Buy	465,316	$32.93	$15,322,855.88
11/12/2014	Vaughn B Himes	EVP	Sell	10,000	$37.52	$375,200.00
11/10/2014	Felix Baker	Director	Buy	1,653,925	$34.56	$57,159,648.00
9/4/2014	Clay B Siegall	CEO	Sell	5,600	$42.54	$238,224.00
8/12/2014	Clay B Siegall	CEO	Sell	11,200	$40.38	$452,256.00
8/11/2014	Clay B Siegall	CEO	Sell	2,700	$40.05	$108,135.00
6/13/2014	Felix Baker	Director	Buy	216,595	$39.92	$8,646,472.40
6/10/2014	Clay B Siegall	CEO	Sell	11,200	$40.14	$449,568.00
6/9/2014	Felix Baker	Director	Buy	546,252	$38.16	$20,844,976.32
6/4/2014	Felix Baker	Director	Buy	281,963	$34.86	$9,829,230.18
5/16/2014	Felix Baker	Director	Buy	189,611	$34.07	$6,460,046.77
4/3/2014	Clay Siegall	CEO	Sell	5,600	$43.34	$242,704.00
2/18/2014	Clay Siegall	CEO	Sell	100,000	$51.97	$5,197,000.00
1/21/2014	Eric Dobmeier	COO	Sell	56,010	$47.92	$2,683,999.20
1/16/2014	Jonathan Drachman	CMO	Sell	1,201	$45.75	$54,945.75
12/16/2013	Felix Baker	Director	Buy	407,078	$39.66	$16,144,713.48
12/5/2013	Felix Baker	Director	Buy	1,005,901	$43.19	$43,444,864.19
10/1/2013	Clay B Siegall	CEO	Sell	2,000	$43.87	$87,740.00
9/10/2013	Eric Dobmeier	COO	Sell	42,000	$46.40	$1,948,800.00
9/5/2013	Eric Dobmeier	COO	Sell	75,000	$42.64	$3,198,000.00
9/3/2013	Clay B Siegall	CEO	Sell	102,000	$43.90	$4,477,800.00
9/3/2013	David W Gryska	Director	Sell	10,000	$42.48	$424,800.00
8/27/2013	Todd Simpson	CFO	Sell	37,763	$41.45	$1,565,276.35
8/19/2013	Clay Siegall	CEO	Sell	7,653	$40.91	$313,084.23
8/19/2013	Eric Dobmeier	COO	Sell	3,328	$40.91	$136,148.48
8/19/2013	Vaughn Himes	EVP	Sell	1,736	$40.91	$71,019.76
8/1/2013	Clay B Siegall	CEO	Sell	2,000	$40.03	$80,060.00
7/12/2013	Todd E Simpson	CFO	Sell	92,527	$37.45	$3,465,136.15
7/1/2013	Clay B Siegall	CEO	Sell	2,000	$32.59	$65,180.00
6/14/2013	Srinivas Akkaraju	Director	Sell	5,000	$32.75	$163,750.00
6/13/2013	Vaughn B Himes	EVP	Sell	10,000	$32.11	$321,100.00
6/3/2013	Clay B Siegall	CEO	Sell	2,000	$33.88	$67,760.00
5/10/2013	Srinivas Akkaraju	Director	Sell	17,500	$37.17	$650,475.00
3/6/2013	Eric Dobmeier	COO	Sell	100,000	$29.68	$2,968,000.00
2/25/2013	David W Gryska	Director	Sell	10,000	$27.17	$271,700.00
2/1/2013	Clay B Siegall	CEO	Sell	2,000	$29.61	$59,220.00
1/15/2013	Thomas C Reynolds	Insider	Sell	125,079	$28.00	$3,502,212.00
11/1/2012	Clay B Siegall	CEO	Sell	8,250	$25.51	$210,457.50
9/4/2012	Clay B Siegall	CEO	Sell	8,250	$26.54	$218,955.00

(Data available from 1/1/2013 forward)

Latest Headlines for Seattle Genetics (NASDAQ:SGEN)

Date	Headline
	Intraday Active Biotech Stocks News: Arrowhead Pharmaceuticals ... - The Voice Registrar (NASDAQ:SGEN) voiceregistrar.com - September 22 at 6:55 PM
	Seattle Genetics Initiates Phase 1 Trial of SGN-CD123A for Patients with Relapsed or Refractory Acute Myeloid Leukemia (NASDAQ:SGEN) finance.yahoo.com - September 19 at 11:50 AM
	8:01 am Seattle Genetics initiates phase 1 clinical trial of SGN-CD123A for patients with relapsed or refractory acute myeloid leukemia (NASDAQ:SGEN) finance.yahoo.com - September 19 at 11:50 AM
	Seattle Genetics Inc (SGEN): Baker Bros. Advisors Raises Stake - Insider Monkey (blog) (NASDAQ:SGEN) www.insidermonkey.com - September 17 at 6:44 PM
	Stock Price Targets in Spotlight: Seattle Genetics, Inc. (NASDAQ ... - Yankee Analysts (NASDAQ:SGEN) yankeeanalysts.com - September 16 at 6:59 PM
	Global Payments Inc. (NYSE:GPN), Seattle Genetics, Inc. (NASDAQ ... - Benzinga (NASDAQ:SGEN) www.benzinga.com - September 16 at 6:59 PM
	Seattle Genetics (SGEN) is Upgraded by Goldman to Neutral (NASDAQ:SGEN) magseriesusa.net - September 16 at 10:50 AM
	Seattle Genetics Inc (SGEN): Baker Bros. Advisors Raises Stake (NASDAQ:SGEN) feedproxy.google.com - September 16 at 8:46 AM
	Seattle Genetics No Longer On Goldman Sachs' Sell List \| Benzinga - Benzinga (NASDAQ:SGEN) www.benzinga.com - September 15 at 7:22 PM
	Intraday Active Biotech Stocks News: Seattle Genetics, Inc. (NASDAQ:SGEN), Halozyme Therapeutics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:SGEN) voiceregistrar.com - September 15 at 10:55 AM
	Seattle Genetics No Longer On Goldman Sachs' Sell List (NASDAQ:SGEN) feeds.benzinga.com - September 15 at 10:22 AM
	Clay B. Siegall Sells 31,269 Shares of Seattle Genetics Inc. (SGEN) Stock (NASDAQ:SGEN) www.nationaldailypress.com - September 14 at 7:26 PM
	Seattle Genetics Inc. (SGEN) Has Risen To A New 52-Week High (NASDAQ:SGEN) www.rttnews.com - September 14 at 7:26 PM
	Aerie Pharmaceuticals Skyrockets On Eye Drug News As Biotechs Bounce (NASDAQ:SGEN) www.investors.com - September 14 at 7:26 PM
	These 5 NASDAQ Stocks Just Hit Their 52-Week Highs (NASDAQ:SGEN) www.insidermonkey.com - September 14 at 11:37 AM
	Trading the Biotech News: Navidea Biopharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:SGEN) voiceregistrar.com - September 13 at 12:07 PM
	Clay B. Siegall Sells 31,269 Shares of Seattle Genetics Inc. (SGEN ... - National Daily Press (NASDAQ:SGEN) www.nationaldailypress.com - September 13 at 12:07 PM
	15,000 shares bought by Seattle Genetics Director (NASDAQ:SGEN) www.nasdaq.com - September 10 at 6:28 PM
	Shares Holding Above Moving Averages: Seattle Genetics, Inc ... - Post News (NASDAQ:SGEN) www.kentuckypostnews.com - September 10 at 11:28 AM
	Stock Stepping Up to a Recent High: Seattle Genetics, Inc ... - Post News (NASDAQ:SGEN) www.kentuckypostnews.com - September 9 at 6:54 PM
	Analysts Valuations For Two Stocks: Seattle Genetics, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:SGEN) voiceregistrar.com - September 9 at 6:54 PM
	Seattle Genetics, Inc. (NASDAQ:SGEN) Trading Up – Insider Trading Activity (NASDAQ:SGEN) www.fidaily.com - September 9 at 12:03 PM
	Brokerage Firm Rating Update on Seattle Genetics (SGEN) (NASDAQ:SGEN) magseriesusa.net - September 8 at 6:57 PM
	Shares of Seattle Genetics (SGEN) Sees Large Inflow of Net Money Flow (NASDAQ:SGEN) larampadinapoli.com - September 8 at 6:57 PM
	Seattle Genetics, Inc. (NASDAQ:SGEN): What is the Sell-side Making of this Stock? - Post News (NASDAQ:SGEN) www.kentuckypostnews.com - September 8 at 11:06 AM
	Trading the Biotech News: Seattle Genetics (NASDAQ:SGEN), Juno ... - The Voice Registrar (NASDAQ:SGEN) voiceregistrar.com - September 8 at 11:06 AM
	Biotech Stocks To Put On Your Watch List: Keryx Biopharmaceuticals Inc. (NASDAQ:KERX), Seattle Genetics, Inc ... - The Voice Registrar (NASDAQ:SGEN) voiceregistrar.com - September 8 at 11:06 AM
	Here's Why Seattle Genetics' Adcetris Is A $2 Billion Product (NASDAQ:SGEN) feeds.benzinga.com - September 7 at 12:26 PM
	Seattle Genetics to Present at Morgan Stanley Global Healthcare Conference (NASDAQ:SGEN) finance.yahoo.com - September 6 at 12:00 PM
	Seattle Genetics, Inc. (NASDAQ:SGEN) Earnings Preview: Should Investors Be Nervous? - The Voice Registrar (NASDAQ:SGEN) voiceregistrar.com - September 3 at 11:29 AM
	Form 4 SEATTLE GENETICS INC For: Aug 31 Filed by: HIMES VAUGHN B (NASDAQ:SGEN) www.streetinsider.com - September 2 at 12:11 PM
	Shares Slipping Lower Over the Past Month: Seattle Genetics, Inc. (NASDAQ:SGEN) - Post News (NASDAQ:SGEN) www.kentuckypostnews.com - September 1 at 10:28 AM
	Form 4 SEATTLE GENETICS INC For: Aug 27 Filed by: SIMPSON TODD E (NASDAQ:SGEN) www.streetinsider.com - August 31 at 12:41 PM
	Seattle Genetics : Technical Roundup on Biotech Stocks -- Keryx Biopharma, Inovio Pharma, Seattle Genetics, and Arrowhead Pharma (NASDAQ:SGEN) www.4-traders.com - August 30 at 10:35 AM
	Seattle Genetics Stock Surges, Execs Sell - Barron's (NASDAQ:SGEN) www.barrons.com - August 26 at 7:01 PM
	[$$] Seattle Genetics Stock Surges, Execs Sell (NASDAQ:SGEN) www.barrons.com - August 26 at 7:01 PM
	ETF’s with exposure to Seattle Genetics, Inc. : August 25, 2016 (NASDAQ:SGEN) www.capitalcube.com - August 25 at 12:29 PM
	Form 4 SEATTLE GENETICS INC For: Aug 23 Filed by: DOBMEIER ERIC (NASDAQ:SGEN) www.streetinsider.com - August 24 at 7:05 PM
	Seattle Genetics, Inc. (NASDAQ:SGEN) Trading Up – Insiders Are Selling (NASDAQ:SGEN) www.fidaily.com - August 23 at 11:54 AM
	Will Seattle Genetics, Inc. (NASDAQ:SGEN) Hit $130 Price Target? - Investor Newswire (NASDAQ:SGEN) www.investornewswire.com - August 20 at 11:20 AM
	This Little Molecule Lets Pivot Pharmaceuticals (PVOTF) Compete With Seattle Genetics (SGEN) - SmallCap Network (NASDAQ:SGEN) www.smallcapnetwork.com - August 18 at 7:38 PM
	Seattle Genetics, Inc. (SGEN) Investment Up in Latest Report from Redmile Group, LLC - Finance Daily (NASDAQ:SGEN) www.fidaily.com - August 16 at 7:27 PM
	Seattle Genetics Has Upcoming Catalysts After All - Seeking Alpha (NASDAQ:SGEN) seekingalpha.com - August 16 at 7:27 PM
	Baillie Gifford & Co Bought A Little More Seattle Genetics, Inc. (SGEN) Stock In The Last Quarter - Finance Daily (NASDAQ:SGEN) www.fidaily.com - August 9 at 7:40 PM
	Recent Analysts Ratings of Stocks: Portola Pharmaceuticals, Inc ... - Street Updates (NASDAQ:SGEN) www.streetupdates.com - August 9 at 7:40 PM
	ETF’s with exposure to Seattle Genetics, Inc. : August 9, 2016 (NASDAQ:SGEN) www.capitalcube.com - August 9 at 7:40 PM
	Seattle Genetics (SGEN) Shares are Down -0.25% – Trade Calls - Trade Calls (NASDAQ:SGEN) www.tradecalls.org - August 9 at 10:38 AM
	Seattle Genetics, Inc. :SGEN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 8, 2016 (NASDAQ:SGEN) www.capitalcube.com - August 8 at 12:10 PM
	Takeda and Seattle Genetics Announce Positive Data from … (NASDAQ:SGEN) www.tmcnet.com - August 2 at 7:45 PM
	SEATTLE GENETICS INC /WA Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:SGEN) biz.yahoo.com - August 1 at 12:58 PM